Pfizer said a much-watched study of its antiviral Paxlovid in patients who have Covid but don't have risk factors for severe disease failed to show a benefit in speeding alleviation of Covid symptoms, but did seem to prevent doctor's visits and hospitalizations.
Pfizer's Paxlovid Study Fails to answer Key Questions
Comment
Show comments
Hide Comments
